Filter
Sort
Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.
The inaugural ISB Virtual Microbiome Series highlighted recent in silico, in vitro, and in vivo advances toward engineering the gut microbiome to resolve complex diseases.
Dr. David Eagleman — bestselling author, TV personality, CEO of Neosensory, adjunct professor at Stanford, TED speaker, and more — was the featured guest at the ISB-Town Hall Seattle event focusing on brain health. His presentation was titled “Can We Create New Senses for Humans?”
Like the draft “shotgun” Human Genome Project of the Human Genome Organization (HUGO), the HPP has now reached a significant decadal milestone of more than 90 percent completion of the Human Proteome that is referred to as the human proteome “parts list.”
ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.
Everybody pees and poops. What if there was a way to use the byproducts of our everyday bodily functions to understand the general health of a population? That is exactly what MIT’s Dr. Eric Alm is pursuing. In an ISB-Town Hall Seattle live stream, Alm discussed the promise of this novel form of public health tracking.